Welcome to our dedicated page for Atai Beckley SEC filings (Ticker: ATAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AtaiBeckley Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common shares and psychiatry-focused investigational drug programs. The company’s regulatory record includes proxy and governance disclosures, shareholder voting matters, operating and financial results, clinical and regulatory updates, and risk-related information tied to development programs such as BPL-003, VLS-01, and EMP-01.
Material-event filings and registration-related documents also cover capital-structure activity, public offering agreements, resale registration matters, and acquisition-related share registration connected with Beckley Psytech. Historical filings under ATAI Life Sciences N.V. and Atai Beckley N.V. provide reference for the company’s corporate transition, financing activity, governance framework, and formal disclosure of business updates.
AtaiBeckley Inc. director and 10% owner Christian Angermayer received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. These options expire on June 4, 2036.
The options will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, provided Angermayer continues to serve on the company's board of directors through the applicable vesting date. Following this grant, his reported option holdings from this award total 121,968 shares.
AtaiBeckley Inc. director Scott Braunstein received two stock option awards. On June 4, 2026, he was granted options covering 86,095 and 121,968 shares of common stock at an exercise price of $4.50 per share, expiring on June 4, 2036.
The options were granted as compensation and not through open-market purchases. According to the footnote, each option will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, provided he continues to serve on the board through the vesting date.
AtaiBeckley Inc. director Laurent Fischer received a stock option grant as equity compensation. The award covers 121,968 shares of common stock at an exercise price of $4.50 per share, expiring on June 4, 2036.
The option will vest on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to Fischer's continued service on the board of directors through the vesting date. Following this grant, he holds stock options for 121,968 underlying shares directly.
AtaiBeckley Inc. director Robert Hershberg received a grant of stock options covering 121,968 shares of common stock. The options have an exercise price of $4.5000 per share and expire on June 4, 2036.
The award vests on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to his continued service on the board through the vesting date. Following this grant, he holds 121,968 stock options directly.
AtaiBeckley Inc. director John Francis Hoffman received a grant of stock options covering 121,968 shares of Common Stock. The options have an exercise price of $4.50 per share and expire on June 4, 2036.
The option award vests on the earlier of the day before AtaiBeckley Inc.'s next annual meeting or June 4, 2027, subject to his continued service on the board of directors through the vesting date. Following this grant, Hoffman holds stock options for 121,968 underlying shares directly.
AtaiBeckley Inc. director Amir H Kalali received a stock option grant as part of his board compensation. The option covers 121,968 shares of common stock with a $4.50 exercise price and expires on June 4, 2036. It vests on the earlier of the day before the company’s next annual meeting or June 4, 2027, subject to his continued service on the board.
AtaiBeckley Inc. director Andrea Heslin Smiley received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. These options vest on the earlier of the day before the company’s next annual meeting or June 4, 2027, contingent on continued board service.
AtaiBeckley Inc. director Sabrina Martucci Johnson received a grant of stock options covering 121,968 shares of common stock at an exercise price of $4.50 per share. The options expire on June 4, 2036 and vest on the earlier of the day before the company’s next annual meeting or June 4, 2027, subject to continued board service.
AtaiBeckley Inc. reported the results of its annual stockholder meeting. As of the April 9, 2026 record date, 366,916,896 common shares were outstanding and entitled to vote, and 203,908,561 shares were represented at the meeting, constituting a quorum.
Stockholders elected Class I directors Sabrina Martucci Johnson, Amir Kalali, M.D., and Andrea Heslin Smiley to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
AtaiBeckley Inc. reported that it will participate in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference, the Oppenheimer CNS and Neuro-Muscular Summit, the 7th Annual HCW Neuro Perspectives Hybrid Conference, and UBS Virtual CNS Day. Management plans to discuss program updates, including initiation of the BPL-003 Phase 3 pivotal ReConnection program, along with other topics. Webcasts for certain events will be available through the company’s investor relations website. The communication is furnished as a Regulation FD disclosure and is accompanied by standard cautionary language about forward-looking statements and related risks.